What Bristol Myers Squibb actually looks for
Bristol Myers Squibb, commonly shortened to BMS and headquartered in New York with major R&D operations in New Jersey, competes directly with Merck in immuno-oncology through Opdivo, and co-markets the blood thinner Eliquis with Pfizer. In 2019, BMS completed its roughly 74 billion dollar acquisition of Celgene, which brought in Revlimid, a major multiple myeloma treatment, but also created real patent-cliff exposure as Revlimid faces generic competition on a negotiated schedule. This means interviewers, especially in strategy and commercial roles, often want to see you understand BMS's pipeline diversification effort as the company works to offset declining Revlimid revenue with newer approvals. BMS operates with a strong oncology and immunology research identity, and candidates should expect detailed scientific questioning in R&D interviews given how directly Opdivo competes against Merck's Keytruda in overlapping cancer indications.
Common questions and how to answer them
How does Opdivo differentiate itself from Keytruda in the immuno-oncology market? A solid answer references specific approved indications where the two drugs compete or diverge, and shows awareness that market share in oncology often comes down to trial data in specific cancer subtypes, not blanket superiority. How should BMS manage the Revlimid patent cliff following the Celgene acquisition? Talk through pipeline investment, newer myeloma treatments, and how large pharma companies typically plan years ahead for anticipated generic competition on a scheduled basis. Tell me about integrating a large acquisition into an existing team or process. Directly relevant to the Celgene deal; use a specific example of merging processes or cultures, even at a smaller scale, and what you learned about integration risk. Across all three, show you understand the Revlimid patent cliff as a real, dated business risk rather than a distant hypothetical, since BMS's near-term strategy is built around managing it.
How to prepare
Understand the Celgene acquisition and Revlimid's patent cliff timeline well enough to discuss how BMS is managing the transition, since this shapes strategic priorities across the company right now. Know how Opdivo positions against Keytruda in oncology, since direct competitor awareness is a common test of genuine industry knowledge in BMS interviews. If in a commercial role, be ready to discuss the Eliquis co-marketing arrangement with Pfizer and what shared commercialization means operationally. Expect commercial and strategy rounds to include a case study on portfolio prioritization given the Revlimid patent cliff, since interviewers want to see how you'd plan for anticipated revenue decline.